(Bloomberg) — Sanofi and Regeneron Pharmaceuticals Inc. are suspending tests on using their rheumatoid arthritis medicine as a potential weapon against Covid-19 after weak results in a final phase of clinical trials.
Shorter hospital stays of patients getting the drug weren’t significant enough in a trial on 420 patients, Sanofi said Tuesday. While critical patients showed a trend to lower fatality rates, that didn’t occur in patients with severe forms of the disease.
The Sanofi and Regeneron effort is one of many programs to evaluate known treatments — from antiviral drugs to plasma from recovered patients — against Covid-19 in stringent clinical tests.
Sanofi Chief Executive Officer Paul Hudson previously described the tests of Kevzara in Covid-19 as a “long shot.”
For more articles like this, please visit us at bloomberg.com
©2020 Bloomberg L.
P.
